Product information and disease descriptionPlace of product in therapyDisease description
Long-term morbidity
8 evidence topics · 9 sources
Usual blood pressure and vascular mortality: one million adults
“Information was obtained on each of one million adults with no previous vascular disease recorded at baseline in 61 prospective observational studies of blood pressure and mortality.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“At ages 40-69 years, each difference of 20 mm Hg usual SBP (or, approximately equivalently, 10 mm Hg usual DBP) is associated with more than a twofold difference in the stroke death rate, and with twofold differences in the death rates from IHD and from other vascular causes.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Excess risk in resistant hypertension: guideline statements
Excess risk in resistant hypertension: Kaiser Permanente Southern California cohort
“We sought to compare the risk of end stage renal disease (ESRD), ischemic heart event (IHE), congestive heart failure (CHF), cerebrovascular accident (CVA), and all-cause mortality among 470,386 individuals with resistant and nonresistant hypertension (non-RH).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Resistant hypertension (cRH and uRH) compared to non-RH, had multivariable adjusted hazard ratios (95% confidence intervals) of 1.32 (1.27–1.37), 1.24 (1.20–1.28), 1.46 (1.40–1.52), 1.14 (1.10–1.19), and 1.06 (1.03–1.08) for ESRD, IHE, CHF, CVA, and mortality, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The risk of ESRD and CVA and were 25% and 23% greater, respectively, in uRH compared to cRH supporting the linkage between blood pressure and both outcomes.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Excess risk in resistant hypertension: incident treated hypertension cohort
“Following multivariable adjustment including baseline patient demographics, comorbidities, study site, and year of study entry, resistant hypertension was associated with increased risk of adverse CV outcomes (HR 1.47, 95% CI 1.33–1.62, p<0.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Excess risk in uncontrolled and true resistant hypertension
“Prospective studies using ABPM have suggested an almost 2-fold increased risk of CVD events in patients with true RH compared with those with hypertension responsive to treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the REGARDS study (Reasons for Geographic and Racial Differences in Stroke), uncontrolled RH was associated with a 2-fold increased risk of coronary heart disease compared with controlled RH.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“BP control reduced the risk of incident stroke, coronary heart disease, or heart failure by 13% among those with RH compared with a 31% lower risk of these outcomes among patients without RH.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In patients with CKD, RH is associated with higher risk of myocardial infarction, stroke, peripheral arterial disease, heart failure, and all-cause mortality compared with patients without RH.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Excess risk in primary aldosteronism
“We identified 31 studies including 3838 patients with primary aldosteronism and 9284 patients with essential hypertension.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“After a median of 8·8 years (IQR 6·2-10·7) from the diagnosis of hypertension, compared with patients with essential hypertension, patients with primary aldosteronism had an increased risk of stroke (odds ratio [OR] 2·58, 95% CI 1·93-3·45), coronary artery disease (1·77, 1·10-2·83), atrial fibrillation (3·52, 2·06-5·99), and heart failure (2·05, 1·11-3·78).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Cardiovascular risk reduction per 5 mm Hg systolic blood pressure: individual participant data meta-analysis
“Data for 344 716 participants from 48 randomised clinical trials were available for this analysis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In this large-scale analysis of randomised trials, a 5 mm Hg reduction of systolic blood pressure reduced the risk of major cardiovascular events by about 10%, irrespective of previous diagnoses of cardiovascular disease, and even at normal or high–normal blood pressure values.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“On average, a 5 mm Hg reduction of systolic blood pressure reduced the risk of a major cardiovascular event by about 10%; the corresponding proportional risk reductions for stroke, heart failure, ischaemic heart disease, and cardiovascular death were 13%, 13%, 8%, and 5%, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Cardiovascular risk reduction per 10 mm Hg systolic blood pressure: trial-level meta-analysis
“We identified 123 studies with 613,815 participants for the tabular meta-analysis.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Every 10 mm Hg reduction in systolic blood pressure significantly reduced the risk of major cardiovascular disease events (relative risk [RR] 0·80, 95% CI 0·77-0·83), coronary heart disease (0·83, 0·78-0·88), stroke (0·73, 0·68-0·77), and heart failure (0·72, 0·67-0·78), which, in the populations studied, led to a significant 13% reduction in all-cause mortality (0·87, 0·84-0·91).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“However, the effect on renal failure was not significant (0·95, 0·84-1·07).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“There was no clear evidence that proportional risk reductions in major cardiovascular disease differed by baseline disease history, except for diabetes and chronic kidney disease, for which smaller, but significant, risk reductions were detected.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote